spacer
home > white papers > Clinical Trials in Russia Orange Paper: 1st Quarter 2014 - Synergy Research Group
WHITE PAPERS
logo_Synergy_Re.JPG

Synergy Research Group

phone +7 495 600 4445
email request@synrg-pharm.com
web http://www.synrg-pharm.com
email 11, 4-Magistralnaya Ul., 123007 Moscow, Russia

Clinical Trials in Russia Orange Paper: 1st Quarter 2014

In summary, Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia:
1. Fast patient enrollment due to the centralized medical infrastructure.
2. Nearly 100% patient retention
3. GCP trained and certified Investigative Sites generating high quality data
4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
Clinical Trials in Russia Orange Paper: 1st Quarter 2014
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

3P Biopharmaceuticals and Nordic Nanovector have extended partnership for Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment

The non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system
More info >>


White Papers

Clinical Research in Spain

BioClever

This whitepaper is on clinical research in Spain, giving a general outline of the main characteristics of research in this country and an overview of the applicable regulations, along with the reasons why Spain is a good place to do research.
More info >>


Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement